The high platelet reactivity is associated with adverse events after stent implantation. Current guidelines consider the measurement of aggregability as a class IIB and there is no information about the routine performance of these measurements. This was a multicenter, prospective, randomized study that included 3800 patients with myocardial infarction. The primary study end point was the incidence of adjustment of the anti-aggregating therapy (dose or drug type) based on test results aggregability. No significant therapy changes were observed, but more often the change of clopidogrel for prasugrel or ticagrelor.
10_tracy_wang
Tracy Wang
2013-10-31
Original title: TRANSLATE-POPS: A Prospective, Cluster-Randomized Trial of Routine Platelet Function Testing in Patients Undergoing PCI